 Investigators planned to administer low 2mg and high 6mg dose slow-release melatonin and the placebo for 4 weeks and evaluate Clinical Global Impression scale, RBD questionnaire, PSQI, Epworth sleepiness scale, and quality of life questionnaire SF-36v2 before and after the treatment along with possible side effects and drug compliance. 